Last reviewed · How we verify
Placebo for celecoxib
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial for celecoxib efficacy evaluation.
At a glance
| Generic name | Placebo for celecoxib |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect, natural disease progression, or regression to the mean rather than direct drug action. In this case, the placebo is being used as a control arm in a Phase 3 trial comparing celecoxib (an active COX-2 inhibitor) to an inactive comparator.
Approved indications
- Control arm in Phase 3 clinical trial for celecoxib efficacy evaluation
Common side effects
- Placebo effect (symptom improvement without active drug)
Key clinical trials
- LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) (PHASE2)
- Celecoxib for ENT Pain Management (PHASE2)
- Preoperative Gabapentin vs Placebo for Vaginal Prolapse Surgery (PHASE4)
- Efficacy and Safety of Ningmitai Capsule Alone or Combined With Celecoxib in the Treatment of CP/CPPS (PHASE4)
- Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients (PHASE1, PHASE2)
- Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome (NA)
- Efficacy and Safety in the Combination of Celecoxib / Pregabalin / Vitamin B for Low Back Chronic Pain (PHASE3)
- Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for celecoxib CI brief — competitive landscape report
- Placebo for celecoxib updates RSS · CI watch RSS
- Pfizer portfolio CI